10,624 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Sciencast Management LP

Sciencast Management LP acquired a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,624 shares of the biopharmaceutical company’s stock, valued at approximately $100,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of FOLD. HealthInvest Partners AB increased its holdings in shares of Amicus Therapeutics by 18.6% in the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after acquiring an additional 51,368 shares during the period. Wellington Management Group LLP increased its holdings in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after acquiring an additional 2,856,101 shares during the period. Tempus Wealth Planning LLC purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $259,000. Neo Ivy Capital Management purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $702,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Amicus Therapeutics by 35.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company’s stock valued at $2,850,000 after acquiring an additional 79,602 shares during the period.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $9.01 on Monday. The stock has a 50-day moving average of $9.35 and a two-hundred day moving average of $10.06. Amicus Therapeutics, Inc. has a one year low of $8.55 and a one year high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a market cap of $2.77 billion, a P/E ratio of -50.06, a P/E/G ratio of 1.51 and a beta of 0.69.

Analyst Ratings Changes

A number of brokerages have recently issued reports on FOLD. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Wells Fargo & Company cut their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.